Advertisement

Early Changes of Gut GVHD: Differential Diagnosis and Criteria for Crypt Cell Apoptosis

  • Cecilia C. S. Yeung
  • David W. Woolston
  • Howard M. ShulmanEmail author
Chapter

Abstract

The early changes of GVHD overlap with those caused by mucosal damage from conditioning chemoradiation therapy. This overlap occurs in the first several weeks post-transplant. The widespread distribution of the mucosal damage including marked edema, hemorrhage, architectural disarray, and crypt atypia suggests chemoirradiation damage. In contrast, the earliest change of GVHD is individual crypt cell apoptosis. The overlap of conditioning toxicity with GVHD is much less likely in patients who receive nonmyeloablative or reduced intensity conditioning. The precise definitions for apoptotic enterocytes, crypt destruction, and crypt abscesses have now been standardized, allowing reliable inter-institutional comparisons. These are important to allow comparison of results from different institutions. A number of other entities cause apoptotic changes resembling GVHD, including infections and some drugs such as NSAIDs, proton pump inhibitors, and mycophenolate mofetil.

Keywords

Crypt cell apoptosis Apoptotic crypt abscess Mucosal damage from chemoirradiation conditioning Exploding crypt cell Gastrointestinal GVHD Pseudo-GVHD 

References

  1. 1.
    Sale GE, Shulman HM, McDonald GB, Thomas ED. Gastrointestinal graft-versus-host disease in man. A clinicopathologic study of the rectal biopsy. Am J Surg Pathol. 1979;3(4):291–9.CrossRefGoogle Scholar
  2. 2.
    Epstein RJ, McDonald GB, Sale GE, Shulman HM, Thomas ED. The diagnostic accuracy of the rectal biopsy in acute graft-versus-host disease: a prospective study of thirteen patients. Gastroenterology. 1980;78(4):764–71.PubMedGoogle Scholar
  3. 3.
    Shulman HM, Cardona DM, Greenson JK, et al. NIH consensus development project on criteria for clinical trials in chronic graft-versus-host disease: II. The 2014 pathology working group report. Biol Blood Marrow Transplant. 2015;21(4):589–603.CrossRefGoogle Scholar
  4. 4.
    Kreft A, Mottok A, Mesteri I, et al. Consensus diagnostic histopathological criteria for acute gastrointestinal graft versus host disease improve interobserver reproducibility. Virchows Arch. 2015;467(3):255–63.CrossRefGoogle Scholar
  5. 5.
    Hall PA, Coates PJ, Ansari B, Hopwood D. Regulation of cell number in the mammalian gastrointestinal tract: the importance of apoptosis. J Cell Sci. 1994;107(Pt 12):3569–77.PubMedGoogle Scholar
  6. 6.
    Saisho Y, Manesso E, Gurlo T, et al. Development of factors to convert frequency to rate for beta-cell replication and apoptosis quantified by time-lapse video microscopy and immunohistochemistry. Am J Physiol Endocrinol Metab. 2009;296(1):E89–96.CrossRefGoogle Scholar
  7. 7.
    Sale GE, Lerner KG, Barker EA, Shulman HM, Thomas ED. The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am J Pathol. 1977;89(3):621–36.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Slavin RE, Dias MA, Saral R. Cytosine arabinoside induced gastrointestinal toxic alterations in sequential chemotherapeutic protocols: a clinical-pathologic study of 33 patients. Cancer. 1978;42(4):1747–59.CrossRefGoogle Scholar
  9. 9.
    Parfitt JR, Driman DK. Pathological effects of drugs on the gastrointestinal tract: a review. Hum Pathol. 2007;38(4):527–36.CrossRefGoogle Scholar
  10. 10.
    Papadimitriou JC, Cangro CB, Lustberg A, et al. Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. Int J Surg Pathol. 2003;11(4):295–302.CrossRefGoogle Scholar
  11. 11.
    Liapis G, Boletis J, Skalioti C, et al. Histological spectrum of mycophenolate mofetil-related colitis: association with apoptosis. Histopathology. 2013;63(5):649–58.PubMedGoogle Scholar
  12. 12.
    Star KV, Ho VT, Wang HH, Odze RD. Histologic features in colon biopsies can discriminate mycophenolate from GVHD-induced colitis. Am J Surg Pathol. 2013;37(9):1319–28.CrossRefGoogle Scholar
  13. 13.
    Marty FM, Winston DJ, Rowley SD, et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N Engl J Med. 2013;369(13):1227–36.CrossRefGoogle Scholar
  14. 14.
    Loeb KR, Yeung CC, Shulman HM. Pathology of hematopoietic cell transplantation. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR, editors. Thomas’ hematopoietic cell transplantation, vol. 1. 5th ed. Chichester: John Wiley & Sons, Ltd.; 2016. p. 292–328.CrossRefGoogle Scholar
  15. 15.
    Otegbeye F, Gale RP, Lazarus HM. Autologous GVHD? Bone Marrow Transplant. 2014;49(11):1349–51.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Cecilia C. S. Yeung
    • 1
    • 2
    • 3
  • David W. Woolston
    • 3
  • Howard M. Shulman
    • 1
    • 2
    • 3
    Email author
  1. 1.Clinical Research DivisionFred Hutchinson Cancer Research CenterSeattleUSA
  2. 2.Department of PathologyUniversity of Washington School of MedicineSeattleUSA
  3. 3.Pathology SectionSeattle Cancer Care AllianceSeattleUSA

Personalised recommendations